Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tarsus Pharmaceuticals (TARS) Other Non Operating Income (2021 - 2025)

Tarsus Pharmaceuticals (TARS) has 5 years of Other Non Operating Income data on record, last reported at $226000.0 in Q3 2025.

  • For Q3 2025, Other Non Operating Income changed N/A year-over-year to $226000.0; the TTM value through Sep 2025 reached -$2.5 million, down 2247.86%, while the annual FY2024 figure was -$1.9 million, 793.43% down from the prior year.
  • Other Non Operating Income reached $226000.0 in Q3 2025 per TARS's latest filing, up from -$145000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $363000.0 in Q4 2023 and bottomed at -$2.5 million in Q4 2024.
  • Average Other Non Operating Income over 5 years is -$207176.5, with a median of -$36000.0 recorded in 2023.
  • Peak YoY movement for Other Non Operating Income: soared 1810.53% in 2023, then plummeted 3116.67% in 2024.
  • A 5-year view of Other Non Operating Income shows it stood at -$953000.0 in 2021, then surged by 101.99% to $19000.0 in 2022, then skyrocketed by 1810.53% to $363000.0 in 2023, then tumbled by 792.29% to -$2.5 million in 2024, then soared by 108.99% to $226000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non Operating Income were $226000.0 in Q3 2025, -$145000.0 in Q2 2025, and -$81000.0 in Q1 2025.